A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Trial Profile

A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Mar 2017 Planned End Date changed from 1 May 2020 to 30 Jul 2020.
    • 17 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 30 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top